INTRODUCTION
============

Dendritic cells (DCs) are potent antigen-presenting cells (APCs) that play major roles in innate and adaptive immune responses [@B001]. DCs express a variety of co-stimulatory surface molecules and MHC class I and II, and are classified into immature DCs and mature DCs according to their phenotype. Immature DCs capture and internalize pathogens via pattern recognition receptors (PRRs) [@B002].

Nontuberculous mycobacteria (NTM) are ubiquitously distributed in the environment [@B003] and cause a wide spectrum of human infections, such as skin and soft tissue infections, lung infections, and opportunistic infections [@B004], in immunocompromised patients such as the HIV-infected individuals [@B005]. *Mycobacterium abscessus* infections present a therapeutic challenge because *M. abscessus* strains are resistant to most antibiotics and linked to high death rate [@B006]. APC-mediated innate and adaptive immune responses are crucial in the protection against *M. abscessus* infections [@B007].

Synthetic agonists of TLR3, TLR4, TLR5, TLR7, TLR8, and TLR9 have been recently identified as suitable immunostimulants of APCs [@B008]. Moreover, on the basis of the efficacy of TLR agonists used thus far, the use of TLR ligands as adjuvants in humans is likely to be developed in the future. Therefore, DC maturation and activation by various microbial through TLRs signaling is the decisive link between innate and adaptive immune responses and is pivotal to the generation of protective immunity.

Recently, Shin *et al.* have shown that *M. abscessus* induces the activation of Raw264.7, a macrophage cell line, through TLR2 [@B007]. Several ligands of TLR2 and TLR4 from mycobacteria have been discovered including LpqH [@B009], LprA [@B010], LprG [@B011], lipomannan [@B012], certain lipoarabinomannan (LAM) species [@B013], phosphatidyl-myo-inositol mannoside [@B014], PE_PGRS [@B015], HBHA [@B016], and CobT [@B017]. Most of the identified ligands of TLR2 were purified from *M. tuberculosis*; however, little is known about the ligands purified from *M. abscessus*. MAB2560 consists of 201 amino acids and is the hypothetical protein of *M. abscessus*. However, there is still little information on MAB2560, and its function in *M. abscessus* remains unknown.

Taken together, our results suggest that MAB2560 is an effective Th1 polarizing adjuvant and that immune stimulation appears to be mediated through activation of DCs by TLR4-mediated MAPKs pathways.

RESULTS
=======

MAB2560 is nontoxic to DCs and enhances DC maturation
-----------------------------------------------------

To examine the immunological effect of MAB2560 on DCs, we purified soluble recombinant MAB2560 using the *Escherichia coli* expression system under endotoxin-free experimental conditions. Using the LAL endotoxin assay kit (GenScript USA, Inc., Piscataway, NJ, USA), we confirmed that endotoxin contamination of MAB2560 had not occurred (＜15 pg/ml). As shown in Supplementary [Fig. 1](#F0001){ref-type="fig"}A, we detected a purified band of MAB2560 in the range of 21 kDa. Next, we investigated the cytotoxicity of MAB2560 against DCs using Annexin V and propidium iodide (PI) staining. We observed no marked change in the percentage of dead cells in DCs stimulated with MAB2560 (up to 2.5 μg/ml concentration) (Supplementary [Fig. 1](#F0001){ref-type="fig"}B). Thus, MAB2560 had no effect on cell death. Furthermore, proteinase K- or heat-treated MAB2560 lost its activity to enhance the levels of CD86 in DCs. However, MAB2560 was resistant to polymyxin B treatment, indicating that LPS contamination was not responsible for the observed effects (Supplementary [Fig. 1](#F0001){ref-type="fig"}).

![MAB2560 induces the maturation of DCs. Immature DCs were treated with MAB2560 (2.5 μg/ml) or LPS (50 ng/ml) for 24 h. (A) The expression of surface markers was analyzed by flow cytometry stained with anti-CD80, anti-CD86, anti-MHC class I, or anti-MHC class II in CD11c^+^ gated cells. The percentages are indicated in the histogram. Results are representative of three experiments with similar data. (B) ELISA was performed to determine the levels of IL-6, TNF-α, IL-1β, IL-12p70, and IL-10 in MAB2560- or LPS-treated DCs. Data are means and SEM of 3 experiments. \*\*P ＜ 0.01 and \*\*\*P ＜ 0.001 compared to medium control. (C) The endocytic capacity of DCs using FITC-conjugated dextran uptake systems was assessed at 37℃ and 4℃ (as a negative control) by flow cytometric analysis. The percentage of FITC-dextran in CD11c^+^ cells is indicated in the dot plot diagram. Results are representative of three experiments with similar data.](BMB-47-512-g0001){#F0001}

To investigate the effect of MAB2560 on the maturation of DCs, we evaluated the co-stimulatory molecules and MHC classes, which are involved in T cell activation. [Fig. 1](#F0001){ref-type="fig"}A shows that MAB2560-treated DCs had increased levels of CD80, CD86, and MHC class I and II. LPS, which is a well-known activator of DC maturation, served as a positive control. Next, we measured the production of pro- and anti-inflammatory cytokines in MAB2560-treated DCs. [Fig. 1](#F0001){ref-type="fig"}B shows that TNF-α, IL-1β, and IL-6 levels significantly increased in MAB2560-treated DCs. whereas the secretion of IL-12, which drives Th1 polarization, was significantly enhanced in MAB2560-treated DCs, and the production of IL-10, which inhibits the function of Th1 immune responses, was not significantly enhanced. Generally, immature DCs have a higher antigen endocytic capacity than mature DCs. Therefore, we examined the influence of MAB2560 on the endocytic capacity of DCs, using the dextran-FITC uptake experiment. MAB2560-treated DCs had diminished endocytic capacity, as expected for mature DCs ([Fig. 1](#F0001){ref-type="fig"}C). On the basis of these results, we inferred that MAB2560 is a potent inducer of DC maturation.

TLR4 is required for the MAB2560-induced maturation of DCs
----------------------------------------------------------

We investigated whether MAB2560 acts through TLRs in DCs. To test the ability of MAB2560 to activate DCs via TLRs, we measured the expression of surface molecules and the production of pro-inflammatory cytokines, such as TNF-α and IL-6, in MAB2560-treated WT, TLR2^-/-^, and TLR4^-/-^ DCs. MAB2560 increased the expression of surface molecules ([Fig. 2](#F0002){ref-type="fig"}A) and the production of pro-inflammatory cytokines ([Fig. 2](#F0002){ref-type="fig"}B) in WT and TLR2^-/-^ DCs. On the other hand, these effects were strongly decreased in TLR4^-/-^ DCs, indicating that MAB2560 is a potent agonist of DC maturation that acts through a TLR4-depedent mechanism. Next, we asked whether MAB2560 could bind to TLR4. Thus, we analyzed the interaction between MAB2560 and TLR4 using the BLItz system. His-tagged recombinant TLR4/MD2 was labeled with an anti-penta-HIS biosensor. Association was started by dipping the TLR4-tagged HIS sensor in buffers of Pam3CSK4, LPS, MAB2560, or PBS (Supplementary [Fig. 3](#F0003){ref-type="fig"}A). MAB2560 bound to TLR4 in a dose-dependent manner, and the concentration-binding rate curve between TLR4 and MAB2560 was calculated (Supplementary [Fig. 3](#F0003){ref-type="fig"}B). Dissociation was started by dipping the biosensor into PBS. The calculated values of Ka, Kd, and KD between MAB2560 and TLR4/MD2 were 1.738e^6^ (1/Ms), 2.281e^-2^ (1/S), and 1.31 nM, respectively. These results indicated that the MAB2560-mediated DC maturation occurred through binding to the TLR-4, rather than the TLR-2, signaling cascade.

![MAB2560 induces the maturation of DCs via TLR4. DCs derived from WT, TLR2^-/-^, or TLR4^-/-^ mice were treated with MAB2560 (2.5 μg/ml) or LPS (50 ng/ml) for 24 h. (A) Histograms show the expression of CD80, CD86, MHC class I, or MHC class II in CD11c^+^-gated cells. The percentages are indicated in the histogram. Results are representative of three experiments with similar data. (B) ELISA was performed to determine the levels of IL-6 and TNF-α in MAB2560- or LPS-treated DCs. Data are means and SEM of 3 experiments.](BMB-47-512-g0002){#F0002}

MAB2560-treated DCs induce the proliferation of CD8^+^ and CD4^+^ T-cells
-------------------------------------------------------------------------

Generally, T cells are stimulated by antigens presented by mature DCs. Naïve T cells are then induced to proliferate and differentiate into effector or helper T cells. To confirm whether MAB2560-treated DCs induce T-cell proliferation, we performed a mixed lymphocyte reaction (MLR) assay using OT-I T cell receptor (TCR) transgenic CD8^+^ T cells and OT-II TCR transgenic CD4^+^ T cells, which express a TCR specific for the MHC class I-restricted OVA peptide 257-264 Ag (OVA~257-264~) and the MHC class II-restricted OVA peptide 323-339 Ag (OVA~323-339~) in DCs, respectively. MAB2560 treatment enhanced the proliferation of CD8^+^ and CD4^+^ T-cells, similar to the LPS-treated group (positive control) ([Fig. 3](#F0003){ref-type="fig"}A). These results demonstrate that MAB2560 is a potent stimulus for the proliferation of CD8^+^ and CD4^+^ T cells via DC activation. In addition, we investigated IFN-*γ* production under MLR conditions. A higher level of IFN-*γ* produced by T-cells primed with MAB2560-treated DCs ([Fig. 3](#F0003){ref-type="fig"}B), indicating that matured DCs stimulated by MAB2560 directly drive naïve T cell polarization toward a Th1 phenotype.

![The activation of DCs by MAB2560 enhances the proliferation of CD8^+^ and CD4^+^ T-cells. (A) OVA~257-264~-specific CD8^+^ T cells were isolated, stained with CFSE, and then co-cultured with immature DCs, OVA~257-264~-pulsed DCs, OVA~257-264~-pulsed MAB2560-treated DCs, or OVA~257-264~-pulsed LPS-treated DCs for 72 h. Histograms showing CD8^+^ T-cell proliferation as assessed by flow cytometry. Results are representative of three experiments with similar data. (B) OVA~323-339~-specific CD4^+^ T cells were isolated, stained with CFSE, and then co-cultured with immature DCs, OVA~323-339~-pulsed DCs, OVA~323-339~-pulsed MAB2560-treated DCs, or OVA~323-339~-pulsed LPS-treated DCs for 72 h. Histograms showing CD8^+^ T-cell proliferation as assessed by flow cytometry. Results are representative of three experiments with similar data. (C) The production of IFN-*γ* was measured in each culture supernatant from (A) and (B) at 72 h by ELISA.](BMB-47-512-g0003){#F0003}

MAPKs are involved in the maturation of DCs
-------------------------------------------

MAPK signaling pathways play a pivotal role in DC maturation [@B018]. Thus, we investigated whether MAB2560 influences MAPKs activation in DCs. MAB2560 activated MAPK pathways, such as p38 MAPK, JNK, and ERK1/2 ([Fig. 4](#F0004){ref-type="fig"}). Furthermore, we tested whether MAPK inhibitors specifically suppresses the MAB2560-induced activation of MAPKs. We found that specific inhibitors of MAPKs specifically inhibited the MAB2560-induced activation of MAPKs (Supplementary [Fig. 4](#F0004){ref-type="fig"}). These results showed that MAB2560 activates the MAPK signaling pathway, and we inferred that DC maturation is through the activation of the above-mentioned signaling cascade.

![MAB2560 activates MAPKs in DCs. For MAPK activation analysis, DCs were treated with MAB2560 (2.5 μg/ml) for 0, 5, 15, 30, 45, and 60 min. Cell lysates were prepared and immunoblotted with antibodies against p-p38 MAPK, p-JNK, p-ERK1/2, and α-tubulin. Results are representative of three experiments with similar data.](BMB-47-512-g0004){#F0004}

DISCUSSION
==========

In this study, MAB2560 was purified and identified from an *M. abscessus* strain in our group for the first time; however, the function of MAB2560 in immune systems has not been studied yet. The recognition of TLRs by various stimuli in DCs is critical for the switch from an immature to a mature phenotype for the leading the effective systemic immune responses. *M. abscessus* has been recently suggested induce the activation of APCs [@B007] and human cells [@B019] via TLR2. However, *M. abscessus*-derived proteins with TLR agonistic effects have not yet been identified. Here, we describe the biological activity and cellular immune responses of *M. abscessus* MAB2560 in DC-mediated T cell immunity and show that TLR4 signaling is involved in the maturation and activation of DCs stimulated by MAB2560.

Several studies have reported that MAPKs, especially ERK1/2 and p38, are key modulators of granuloma formation during NTM infection [@B020]. Consistent with these reports, our result showed the activation of MAPKs in MAB2560-treated DCs. Thus, the activation of MAPKs by MAB2560 is a potent mechanism underlying the enhancement of IL-12 production in DCs. Taken together, our findings suggest that MAB2560 enhances DC maturation via TLR4 and elicits MAPKs-mediated production of IL-12. The induction of IL-12 production is then responsible for activating and polarizing the naïve CD4^+^ T cells toward Th1 cells that produce IFN-*γ*. The production of IFN-*γ* in PBMCs is represents to be severely compromised in patients with tuberculosis [@B021]. In this regard, IFN-*γ* is critically important in the host defense against to *M. abscessus* [@B022].

In this study, MAB2560 establishes a link between the innate DCs function and the adaptive Th1 immunity to *M. abscessus*. The characteristic of the bacterial pathogens that are encountered by the adaptive immune response tailors the balance of the Th1/Th2 response to a particular pathogen [@B023]. Our results suggest that *M. abscessus* MAB2560 stimulates DCs and specifically produces the Th1 immunity *ex vivo*. The enhancement of IL-12 production by DCs and IFN-*γ* by T cells is strongly evaluated by MAB2560 stimulation.

In conclusion, MAB2560 is a potent protein that induces DCs maturation and Th1-mediated responses. Understanding the mechanism about how MAB2560 modulates the function of DCs may contribute to vaccine development against *M. abscessus* infection. Further understanding of the mechanism by which MAB2560 regulates the DC function may aid in the development of effective *M. abscessus* vaccines and an effective immunotherapy adjuvant for other infectious diseases. Moreover, identification of mycobacterial antigens as an adjuvant that induces the activation of APCs may affect the development of immunotherapy in the future.

MATERIALS AND METHODS
=====================

Animals
-------

Female (4-6 weeks old) C57BL/6 (H-2K^b^ and I-A^b^) mice were purchased from the Korean Institute of Chemistry Technology (Daejeon, Korea). C57BL/6 OT-I T-cell receptor (TCR) transgenic mice, C57BL/6 OT-II TCR transgenic mice, C57BL/6J TLR2^-/-^ (B6.129-Tlr2tm1Kir/J), and C57BL/10 TLR4^-/-^ (C57BL/ 10ScNJ) were purchased at 6 to 8 weeks of age from The Jackson Laboratory (Bar Harbor, ME). All mice were housed in a specific pathogen-free environment and used in accordance with the institutional guidelines for animal care.

Reagents and antibodies
-----------------------

Recombinant murine granulocyte-macrophage colony-stimulating factor (rmGM-CSF) and rmIL-4 were purchased from R&D Systems (Minneapolis, MN). Cytokine enzyme-linked immunosorbent assay (ELISA) kits for murine IL-12p70, TNF-α, IL-10, IL-1β, and IL-6 were purchased from R&D Systems. Fluorescein isothiocyanate (FITC)- or phycoerythrin (PE)-conjugated monoclonal antibodies (mAbs) used to detect the expression of CD11c (HL3), CD80 (16-10A1), CD86 (GL1), IAb β-chain (AF-120.1), and H2Kb (AF6-88.5) by flow cytometry, as well as isotype-matched control mAbs and the biotinylated anti-CD11c (N418) mAb, were purchased from R&D Systems. Antibodies against phospho-ERK, ERK, phospho-p38, phospho-JNK, and tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).

Expression and purification of MAB2560 from E. coli
---------------------------------------------------

MAB2560 gene was amplified by PCR using *M. abscessus* genomic DNA (ATCC19977) as a template and the following primers: forward, 5\'-[CAT ATG]{.ul} ACG AGC GTT GAC GTG CCC TCG-3\', and reverse, 5\'-[AAG CTT]{.ul} TAG GCC GGA GGG CAC GAC CTT-3\'. The PCR product was cut with *NdeI* and *Hind*III and then inserted into pET28a vector cut with the same restriction enzymes. The recombinant plasmid was transformed into *E. coli* BL21 cells carrying bacteriophage DE3 for protein overexpression. Recombinant MAB2560 was produced from *E. coli* (rEC-MAB2560). Recombinant *E. coli* (pET22b-MAB2560) cells were incubated in LB medium (100 μg/ml ampicillin) at 37℃ for 12 h. Next, the cells were treated with 1 mM isopropyl-β-D-thio-galactoside (IPTG) and incubated at 37℃ for 6 h. The cells were lysed in lysis buffer (1 M DDT, lysozyme, PMSF) and sonicated. Vector control cells (pET-BL21) were treated in the same manner. The products from each cell was separated by 13.5% SDS-PAGE and visualized by Coomassie blue staining. Lastly, 6X His-tagged MAB2560 attached to a Ni-NTA column was purified using imidazole (50 and 100 mM) and treated with *Tachypleus* amebocyte lysate (TAL) assay for eliminating the endotoxin in the fusion protein.

Generation and culture of murine bone marrow-derived dendritic cells
--------------------------------------------------------------------

Primary culture of DCs was performed as previously described [@B024], [@B025].

Flow cytometric analysis of the expression of surface molecules
---------------------------------------------------------------

Flow cytometic analysis to detect the expression of CD80, CD86, MHC class I and MHC class II in CD11c positive cells were experimented according to the procedure of Park *et al.* [@B023].

Antigen uptake quantitation
---------------------------

Briefly, 2×10^5^ cells were equilibrated at 37℃ or 4℃ for 45 min and then pulsed with 1 mg/ml FITC-conjugated dextran, which was stopped with cold staining buffer. Washed cells were stained with PE-conjugated anti-CD11c and analyzed using a FACSCalibur flow cytometer.

Cytokine assay
--------------

Murine IL-12p70, IL-10, IL-1β, IL-6, and TNF-α were measured using an ELISA kit according to the manufacturer's instructions.

Western blot analysis
---------------------

Western bot analysis was experimented according to the procedure of Lee *et al.* [@B024].

Mixed lymphocyte reaction
-------------------------

Mixed lymphocyte reaction analysis was experimented according to the procedure of Lee *et al.* [@B024].

Statistical analysis
--------------------

All experiments were repeated at least 3 times with consistent results. Unless otherwise stated, data are expressed as mean ± SEM. Analysis of variance was used to compare experimental groups with control values, while comparisons between multiple groups were made using Tukey's multiple comparison tests (Prism 3.0 GraphPad software). A *P* value of less than 0.05 was considered to indicate statistical significance.
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